These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9377842)

  • 1. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model for the future conduct of pharmacovigilance.
    Waller PC; Evans SJ
    Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 5. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacovigilance in pharmacy practice].
    Duquet N
    J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An appraisal of spontaneous adverse event monitoring.
    Fletcher AP
    Adverse Drug React Toxicol Rev; 1992; 11(4):213-27. PubMed ID: 1489882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 9. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmarketing surveillance.
    Vlahović-Palčevski V; Mentzer D
    Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
    Mariani L; Minora T; Ventresca GP
    Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

  • 13. Web-based intensive monitoring: from passive to active drug surveillance.
    Härmark L; van Grootheest K
    Expert Opin Drug Saf; 2012 Jan; 11(1):45-51. PubMed ID: 22007719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 15. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety--important to us all!
    Böttiger LE
    J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
    [No Abstract]   [Full Text] [Related]  

  • 17. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacovigilance update].
    Livio F; Biollaz J; Buclin T
    Rev Med Suisse; 2011 Jan; 7(277):71-4. PubMed ID: 21309181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.